Valeant Pharmaceuticals International (VRX) : 4 brokerage houses believe that Valeant Pharmaceuticals International (VRX) is a Strong Buy at current levels. 8 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Valeant Pharmaceuticals International (VRX). Zacks Investment Research suggests a Strong Sell with a rank of 5. 3 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 15 Wall Street Analysts endorse the stock as a Hold with a rating of 2.87.
Valeant Pharmaceuticals International (VRX) : 12 investment research analysts covering Valeant Pharmaceuticals International (VRX) have an average price target of $39.75 for the near short term. The highest target price given by the Brokerage Firm to the stock is $90 and the lowest target is $11 for the short term. Analysts expect the variance to be within $19.53 of the average price.
Valeant Pharmaceuticals International (NYSE:VRX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $20.08 and $19.61 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $23.14. The buying momentum continued till the end and the stock did not give up its gains. It closed at $23.06, notching a gain of 15.59% for the day. The total traded volume was 47,089,682 . The stock had closed at $19.95 on the previous day.
Also, BMO Capital initiates coverage on Valeant Pharmaceuticals International (NYSE:VRX). The current rating of the shares is Market Perform, according to the research report released by the firm. The rating by the firm was issued on June 29, 2016. The company shares have dropped -91.11% from its 1 Year high price. On Aug 6, 2015, the shares registered one year high at $263.81 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $24.50 and the 200 Day Moving Average price is recorded at $53.50.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.